On a scale of 0 to 100, Integrated Biopharma holds a performance score of 7. The company retains a Market Volatility (i.e., Beta) of -0.8, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Integrated Biopharma are expected to decrease at a much lower rate. During the bear market, Integrated Biopharma is likely to outperform the market. Please check Integrated Biopharma's potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Integrated Biopharma's current trending patterns will revert.
Risk-Adjusted Performance
Fair
Weak
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Integrated Biopharma are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile fundamental drivers, Integrated Biopharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow
210 K
Total Cashflows From Investing Activities
-465 K
Integrated
Integrated Biopharma Relative Risk vs. Return Landscape
If you would invest 31.00 in Integrated Biopharma on October 7, 2025 and sell it today you would earn a total of 7.00 from holding Integrated Biopharma or generate 22.58% return on investment over 90 days. Integrated Biopharma is currently generating 0.4062% in daily expected returns and assumes 4.1557% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of otc stocks are less volatile than Integrated, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days Integrated Biopharma is expected to generate 5.63 times more return on investment than the market. However, the company is 5.63 times more volatile than its market benchmark. It trades about 0.1 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.11 per unit of risk.
Integrated Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Integrated Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Integrated Biopharma, and traders can use it to determine the average amount a Integrated Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0978
Best Portfolio
Best Equity
Good Returns
Average Returns
Small Returns
INBP
Cash
Small Risk
Average Risk
High Risk
Huge Risk
Negative Returns
Based on monthly moving average Integrated Biopharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Integrated Biopharma by adding it to a well-diversified portfolio.
Integrated Biopharma Fundamentals Growth
Integrated OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Integrated Biopharma, and Integrated Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Integrated OTC Stock performance.
Assessing Integrated Biopharma's fundamental ratios provides investors with valuable insights into Integrated Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Integrated Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 147 people.
Things to note about Integrated Biopharma performance evaluation
Checking the ongoing alerts about Integrated Biopharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Integrated Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Integrated Biopharma has some characteristics of a very speculative penny stock
Integrated Biopharma had very high historical volatility over the last 90 days
About 69.0% of the company shares are held by company insiders
Evaluating Integrated Biopharma's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Integrated Biopharma's otc stock performance include:
Analyzing Integrated Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Integrated Biopharma's stock is overvalued or undervalued compared to its peers.
Examining Integrated Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Integrated Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Integrated Biopharma's management team can help you assess the OTC Stock's leadership.
Pay attention to analyst opinions and ratings of Integrated Biopharma's otc stock. These opinions can provide insight into Integrated Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Integrated Biopharma's otc stock performance is not an exact science, and many factors can impact Integrated Biopharma's otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for Integrated OTC Stock Analysis
When running Integrated Biopharma's price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.